Latest News on PCRX

Financial News Based On Company


Advertisement
Advertisement

Merger converts 32,675 director options into a cash right at Pacira BioSciences (PCRX).

https://www.stocktitan.net/sec-filings/PCRX/form-4-pacira-bio-sciences-inc-insider-trading-activity-562854500541.html
Pacira BioSciences director Thomas G. Wiggans disposed of 32,675 stock options on November 17, 2026, the effective date of a merger with Viatris Inc. These options were canceled and converted into a cash right based on the $36.50 per-share offer price minus the $23.42 per-share exercise price, subject to tax withholding. After this transaction, Wiggans reported zero remaining options.

Viatris closes $1.65 billion Pacira buy, adding $90 million to $100 million of 2026 sales

https://www.quantisnow.com/articles/viatris-closes-pacira-deal-with-90-to-100-million-of-2026-revenue-guided
Viatris completed its $1.65 billion all-cash acquisition of Pacira BioSciences on November 17, 2026, purchasing shares at $36.50 each. The deal, which adds two patent-protected pain management drugs to Viatris's portfolio, is expected to contribute $90 million to $100 million in revenue by year-end 2026. This acquisition represents a strategic move for Viatris into branded pain drugs, complementing its own non-opioid pain candidate, fast-acting meloxicam, awaiting an FDA decision.

Pacira BioSciences Announced Transfer or Voluntary Withdrawal of Listing

https://www.tradingview.com/news/tradingview:2a9baddf9d46a:0-pacira-biosciences-announced-transfer-or-voluntary-withdrawal-of-listing/
Pacira BioSciences (PCRX) announced its intention to delist its shares and deregister them under Section 12(b) following the completion of its merger with Viatris. The company also plans to file Form 15 to terminate registration under Section 12(g) and suspend its Exchange Act reporting obligations. This decision was made on November 17, 2026, and a request for a trading halt has been sent to Nasdaq.

About 66.46% tendered, Pacira BioSciences (PCRX) is set to merge without a stockholder vote.

https://www.stocktitan.net/sec-filings/PCRX/sc-to-t-a-pacira-bio-sciences-inc-amended-third-party-tender-offer-cf86e72cf91a.html
Viatris subsidiary Peach Purchaser Sub's tender offer for Pacira BioSciences (PCRX) at $36.50 per share has successfully concluded. Approximately 66.46% of outstanding shares were validly tendered, meeting the minimum condition for the merger. As a result, Peach Purchaser Sub will merge into Pacira BioSciences on November 17, 2026, without requiring a stockholder vote, after which Pacira shares will be delisted from Nasdaq.

Pacira BioSciences (PCRX) complied with Nasdaq’s voluntary withdrawal rules.

https://www.stocktitan.net/sec-filings/PCRX/25-nse-pacira-bio-sciences-inc-sec-filing-317302d7fc8a.html
Pacira BioSciences, Inc. (PCRX) has filed a Form 25 with Nasdaq for the voluntary withdrawal of its common stock from listing and registration. Nasdaq has certified that Pacira complied with the necessary rules and requirements for this voluntary withdrawal. This action signifies the company's delisting from the Nasdaq Stock Market.
Advertisement

Viatris subsidiary offers $36.50 for each Pacira BioSciences (PCRX) share.

https://www.stocktitan.net/sec-filings/PCRX/sc-to-t-a-pacira-bio-sciences-inc-amended-third-party-tender-offer-0d10b07a7c2e.html
Viatris Inc.'s wholly-owned subsidiary, Peach Purchaser Sub Inc., has launched a tender offer to acquire all outstanding shares of Pacira BioSciences (PCRX) for $36.50 per share in cash. This amendment to the tender offer statement primarily updates the litigation disclosure, noting that two Pacira stockholders have filed complaints in New York state court seeking to block the merger or obtain damages due to allegedly omitted merger disclosures. Pacira and Viatris intend to vigorously defend against these actions, believing their disclosures comply with applicable law.

Ingram Micro to join S&P SmallCap 600, replacing Pacira BioSciences

https://www.tradingview.com/news/seekingalpha:48435e27c094b:0-ingram-micro-to-join-s-p-smallcap-600-replacing-pacira-biosciences/
Ingram Micro Holding (INGM) is set to join the S&P SmallCap 600, replacing Pacira BioSciences (PCRX), effective before market open on November 17, 2026. This change is due to Pacira BioSciences being acquired by Viatris (VTRS). Following the announcement, Ingram Micro's stock price increased by approximately 3% in pre-market trading.

What Pacira BioSciences Doubters Got Wrong

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/what-pacira-biosciences-doubters-got-wrong-1
Pacira BioSciences saw a 49.2% return, including dividends, from the start of the year, despite skepticism. Bullish arguments in 2025 focused on CMS policy shifts, ambulatory surgery growth, and a Johnson & Johnson MedTech partnership, while bears highlighted reliance on EXPAREL and generic threats. The recent US$36.50 per share cash tender from Viatris, coupled with improved profitability on flatter revenue, suggests the optimists were more accurate.

Pacira BioSciences (PCRX) After Earnings Surprise Is The Stock Already Fully Valued

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/pacira-biosciences-pcrx-after-earnings-surprise-is-the-stock
Pacira BioSciences (PCRX) recently reported third-quarter results showing a revenue dip but a significant jump in profitability. The stock has seen substantial gains recently, with a 90-day return of 49.12% and a year-to-date gain of 48.94%. While Simply Wall St's narrative suggests the stock is modestly overvalued at $36.43 against a fair value of $33.57, a different discounted cash flow model indicates it could be significantly undervalued.

Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

https://www.businesswire.com/news/home/20261105961378/en/Pacira-BioSciences-Investor-Alert-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-Pacira-BioSciences-Inc.---PCRX
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). The law firm is examining whether the offered price of $36.50 per share in cash adequately values Pacira BioSciences and whether the process leading to this transaction was fair. KSF encourages shareholders who believe the transaction undervalues the company or wish to discuss their legal rights to contact them, noting the time-sensitive nature of the tender offer.
Advertisement

Revenue falls to $177M, but profit rises at Pacira BioSciences (PCRX).

https://www.stocktitan.net/sec-filings/PCRX/10-q-pacira-bio-sciences-inc-quarterly-earnings-report-82eaeaf78f9a.html
Pacira BioSciences (PCRX) reported a slight decrease in third-quarter 2026 revenue to $176.653 million from $179.516 million year-over-year. Despite the revenue dip, net income significantly increased to $28.521 million compared to $5.432 million in the prior year, alongside higher operating income and nine-month operating cash flow. The company's proposed acquisition by Viatris Inc. for $36.50 per share is expected to close by year-end 2026.

Does Pacira BioSciences (PCRX) Justify Its Price With Earnings?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/does-pacira-biosciences-pcrx-justify-its-price-with-earnings
Pacira BioSciences (PCRX) has received a cash tender offer of US$36.50 per share from Viatris, which is significantly above its pharmaceuticals industry P/E average. The article explores whether this price is justified by Pacira's earnings profile, noting its high P/E of 99.1x compared to an industry average of 16.1x. Community narratives on Simply Wall St are split between a bull case that sees potential for improved operating margins and a bear case concerned about reliance on EXPAREL and expiring reimbursement policies.

PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders

https://www.mycarrollcountynews.com/online_features/press_releases/article_6dc11358-f9cd-5a41-9b2a-97de572850f4.html
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Pacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share in cash. The firm is examining whether Pacira and its board failed to obtain the best possible price for shareholders, conduct a fair sales process, and disclose all material information. Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief for shareholders.

From early adoption to broader use: My experience with non-opioid options as an anesthesiologist

https://www.bizjournals.com/washington/news/2026/10/30/adoption-broader-use-non-opioid-anesthesiologist.html
Dr. Sanford Littwin, an anesthesiologist, discusses his early adoption and increasing use of non-opioid pain management options like EXPAREL for surgical patients. He highlights the benefits of these alternatives in minimizing opioid-related side effects and promoting smoother recoveries. The article encourages patients to proactively ask their healthcare providers about non-opioid options before surgery.

Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings Growth

https://uk.finance.yahoo.com/news/pacira-biosciences-pcrx-reports-next-130031844.html
Pacira BioSciences (PCRX) is expected to report earnings next week, with Wall Street anticipating a year-over-year increase in earnings and revenues for the quarter ended September 2026. The company is projected to post quarterly earnings of $0.76 per share and revenues of $183.42 million. With a positive Earnings ESP of +0.87% and a Zacks Rank of #3, Pacira BioSciences is predicted to beat the consensus EPS estimate.
Advertisement

US695127AJ9 Bond Profile: Coupon and Redemption

https://www.tradingview.com/symbols/FWB-US695127AJ9/profile/
This article provides a detailed profile of the Pacira Biosciences, Inc. 2.125% bond, identified by US695127AJ9, maturing on May 15, 2029. It outlines key facts such as the issuer, issue and maturity dates, face value, and minimum denomination. The profile also details interest payment specifics, including the semi-annual coupon frequency, fixed rate, and a schedule of upcoming payouts.

ETFs Are Net Sellers of Pacira BioSciences (PCRX) on Oct. 22

https://www.gurufocus.com/news/9141963/etfs-are-net-sellers-of-pacira-biosciences-pcrx-on-oct-22?utm_source=yahoo_finance&utm_medium=syndication&utm_campaign=headlines&r=caf6fe0e0db70d936033da5461e60141
On October 22, six ETFs collectively sold $10.5 million worth of Pacira BioSciences (PCRX) stock, marking the fifth consecutive session of net outflows for the company. The largest sellers included DFSV, DFAT, and DFAS, with DFSV significantly cutting its stake. Pacira BioSciences, a specialty pharmaceutical company, has seen a recent trend of net selling by ETFs over the last five reported days.

Pacira BioSciences, Inc. Estimates – NASDAQ:PCRX

https://www.tradingview.com/symbols/NASDAQ-PCRX/financials-estimates/
This article provides an overview of Pacira BioSciences, Inc. (NASDAQ: PCRX) financials and estimates available on TradingView. It directs users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform allows comparison of actual results with average, high, and low estimates, and visualization of trends over time.

HC Wainwright cuts target for Pacira BioSciences stock to USD 36.50

https://www.ad-hoc-news.de/boerse/news/nebenwerte/hc-wainwright-cuts-target-for-pacira-biosciences-stock-to-usd-36-50/70378393
HC Wainwright has reduced its price target for Pacira BioSciences (PCRX) stock to USD 36.50 from USD 38.00 and downgraded it to Hold. This adjustment comes as Pacira reported second-quarter revenue of USD 192.40 million and is scheduled to release its third-quarter 2026 earnings on October 29, 2026, which will be crucial following a revised full-year revenue outlook after its iovera divestiture. The new target is slightly above the stock's recent Nasdaq closing price, with the stock trading near its 52-week high.

Pacira BioSciences stock at USD 36.34 on October 16, 2026, 0.90 percent below high

https://www.ad-hoc-news.de/boerse/news/nebenwerte/pacira-biosciences-stock-at-usd-36-34-on-october-16-2026-0-90-percent-below-high/70350684
Pacira BioSciences (PCRX) stock closed at USD 36.34 on October 16, 2026, just 0.90 percent below its 52-week high of USD 36.67. The company reported second-quarter revenue of USD 192.40 million, a 6.20 percent year-over-year increase, and adjusted earnings per share of USD 0.73, surpassing consensus estimates. Royal Bank of Canada recently raised its price target for PCRX to USD 36.50.
Advertisement

Pacira BioSciences, Inc. - Common Stock (Nasdaq:PCRX) Stock Quote

https://markets.financialcontent.com/stocks/quote/nq:pcrx
This article provides a stock quote and financial data for Pacira BioSciences, Inc. (PCRX), including its current trading price, daily range, 52-week performance, and volume. It also highlights recent news, such as an investigation into a proposed sale, and various corporate announcements. The company's stock has shown strong performance over the past year, significantly outperforming major market indices.

Royal Bank of Canada lifts target for Pacira BioSciences stock to USD 36.50

https://www.ad-hoc-news.de/boerse/news/nebenwerte/royal-bank-of-canada-lifts-target-for-pacira-biosciences-stock-to-usd/70331423
Royal Bank of Canada has increased its price target for Pacira BioSciences (PCRX) stock to USD 36.50 from USD 25.00, maintaining a "sector perform" rating. This adjustment comes after Pacira reported a 6.20% year-over-year revenue increase in the second quarter of 2026, reaching USD 192.40 million. The stock is currently trading near its 52-week high, with a market capitalization of USD 1.4 billion and a P/E ratio of 103.49.

Seven investors report stakes below 5% in Pacira BioSciences (PCRX).

https://www.stocktitan.net/sec-filings/PCRX/schedule-13d-a-pacira-bio-sciences-inc-amended-major-shareholder-repo-f9c7a53004e2.html
A Schedule 13D amendment for Pacira BioSciences (PCRX) indicates that seven reporting persons, including DOMA Perpetual Capital Management LLC and The John Templeton Foundation, ceased to be beneficial owners of more than 5% of the common shares as of October 8, 2026. Each reporting person now lists 0 shares and 0% beneficial ownership. The ownership percentage calculation is based on 39,861,886 common shares outstanding as of August 3, 2026.

Form 13D/A Pacira BioSciences For: 13 October By Investing.com

https://in.investing.com/news/stock-market-news/form-13da-pacira-biosciences-for-13-october-93CH-5631543
This article announces the filing of Form 13D/A for Pacira BioSciences on October 13th, as reported by Investing.com. It is a brief news item indicating a regulatory filing related to the company. The content primarily consists of market data, other news headlines, and navigational elements rather than details about the filing itself.

Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

https://www.businesswire.com/news/home/20261012418467/en/Pacira-BioSciences-Investor-Alert-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-Pacira-BioSciences-Inc.---PCRX
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. for $36.50 per share in cash. The law firm is examining whether this consideration and the process leading to the transaction are adequate or if the company is undervalued. Shareholders are encouraged to contact KSF to discuss their legal rights, especially given the tender offer structure of the transaction.
Advertisement

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)

https://www.morningstar.com/news/pr-newswire/20261011dc69496/shareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-pacira-biosciences-inc-nasdaq-pcrx
Monteverde & Associates PC has launched an investigation into Pacira BioSciences, Inc. (NASDAQ: PCRX) concerning its proposed sale to Viatris Inc. Shareholders are expected to receive $36.50 in cash per share, and the firm is evaluating if this is a fair deal. Shareholders are encouraged to contact Juan Monteverde for more information regarding their rights.

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)

https://www.prnewswire.com/news-releases/shareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-pacira-biosciences-inc-nasdaq-pcrx-302905162.html
Monteverde & Associates PC, a class action firm, has announced an investigation into Pacira BioSciences, Inc. (NASDAQ: PCRX) regarding its proposed sale to Viatris Inc. Shareholders are expected to receive $36.50 in cash per share, and the firm is investigating whether this is a fair deal. The firm encourages Pacira shareholders to contact them for a free consultation.

Pacira BioSciences SVP Lauren Riker sells $217,920 in stock

https://www.investing.com/news/insider-trading-news/pacira-biosciences-svp-lauren-riker-sells-217920-in-stock-93CH-4942682
Lauren Riker, Senior Vice President of Finance at Pacira BioSciences, Inc. (NASDAQ:PCRX), sold 6,000 shares of company stock for $217,920 on October 8, 2026, after acquiring them through stock options. The sale was executed under a Rule 10b5-1 trading plan, following a significant 44% surge in the stock. This transaction comes amidst recent company developments including a revenue increase, Viatris's acquisition of Pacira Pharmaceuticals, and an "outperform" rating from Oppenheimer.

Pacira BioSciences SVP Lauren Riker sells $217,920 in stock

https://www.investing.com/news/insider-trading-news/pacira-biosciences-svp-lauren-riker-sells-217920-in-stock-93CH-4942219
Lauren Riker, Senior Vice President of Finance at Pacira BioSciences, sold 6,000 shares of the company's stock for $217,920 after exercising options. This transaction was conducted under a Rule 10b5-1 trading plan, and Ms. Riker now holds over 62,000 shares. The sale occurred as the stock neared its 52-week high, with InvestingPro analysis suggesting it remains undervalued.

After exercising options, Lauren Riker sells 6,000 Pacira BioSciences (PCRX) shares.

https://www.stocktitan.net/sec-filings/PCRX/form-4-pacira-bio-sciences-inc-insider-trading-activity-4d6037e35452.html
Lauren Riker, Senior Vice President of Finance at Pacira BioSciences (PCRX), exercised options for 6,000 common shares at $32.35 per share and subsequently sold them at $36.32 per share on October 8, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan established on March 12, 2026. After the sale, Riker's direct common stock holdings in PCRX amounted to 62,284.242 shares, with her stock option position reduced to zero.
Advertisement

PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.

https://www.morningstar.com/news/pr-newswire/20261008cg67044/pcrx-shareholder-alert-ademi-llp-investigates-whether-buyout-fairly-values-pacira-biosciences-inc
Ademi LLP is investigating whether the proposed acquisition of Pacira (NASDAQ: PCRX) by Viatris for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion, provides fair value to Pacira's public shareholders. The investigation will focus on the exchange ratio, change-of-control benefits for insiders, restrictions on competing offers, and the conduct of Pacira's Board of Directors. Shareholders are encouraged to contact Ademi LLP to discuss their rights.

PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.

https://www.prnewswire.com/news-releases/pcrx-shareholder-alert-ademi-llp-investigates-whether-buyout-fairly-values-pacira-biosciences-inc-302902663.html
Ademi LLP is investigating whether the proposed acquisition of Pacira (NASDAQ: PCRX) by Viatris for $36.50 per share fairly values the company for its public shareholders. The firm is examining the deal price, benefits for company insiders, restrictions on competing offers, and the Pacira Board's conduct during negotiations. Shareholders are invited to contact Ademi LLP to discuss their rights.

Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday

https://www.benzinga.com/news/26/10/62246680/helen-of-troy-posts-upbeat-q2-earnings-joins-pacira-biosciences-wolfspeed-and-other-big-stocks-moving-higher-on-thursday
Helen of Troy Limited (NASDAQ: HELE) shares surged after reporting better-than-expected Q2 adjusted EPS and raising its FY27 GAAP EPS guidance. Other companies like Pacira Biosciences (NASDAQ: PCRX) and Wolfspeed (NYSE: WOLF) also saw significant gains due to acquisitions and conditional loan commitments, respectively. The article highlights several big stocks experiencing notable upward movements during Thursday's trading session.

Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home

https://www.globenewswire.com/news-release/2026/10/07/3376427/0/en/pacira-biosciences-and-caregiver-action-network-announce-new-survey-on-gaps-in-preparing-families-for-postsurgical-recovery-at-home.html
Pacira BioSciences and Caregiver Action Network (CAN) released findings from their "Ready, Set, Recover" initiative, highlighting a significant gap in preparing family caregivers for postsurgical recovery at home. A survey of CAN's network revealed that caregivers often lack clear pain management plans, early education on non-opioid options, and practical support, despite being largely responsible for managing postsurgical care. The findings emphasize the need for earlier involvement of caregivers in discussions and provision of detailed plans before surgery to improve the hospital-to-home transition.

Pacira BioSciences (PCRX) On Its Molteni Deal And The Undervalued Narrative

https://finance.yahoo.com/healthcare/articles/pacira-biosciences-pcrx-molteni-deal-200829338.html
Pacira BioSciences (PCRX) recently partnered with Molteni Farmaceutici to distribute its non-opioid pain drug EXPAREL across Europe. Despite a recent share price dip, the stock is positive year-to-date, with some analysts seeing it as 34% undervalued based on a $38 fair value, while others find it expensive on earnings. The long-term earnings power is potentially supported by extended patent protection for EXPAREL until 2039.
Advertisement

PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal

https://www.tradingview.com/news/zacks:f195d72cf094b:0-pcrx-expands-exparel-commercial-reach-in-europe-through-molteni-deal/
Pacira BioSciences (PCRX) has entered into an exclusive agreement with Molteni Farmaceutici to distribute and commercialize Exparel in the EU and the United Kingdom. This partnership leverages Molteni's pain management expertise and distribution network to expand Exparel's access in key European markets, with initial launches planned for Italy, Germany, Austria, and Poland in 2027. The deal is expected to provide Pacira with upfront payments, supply prices, and royalties, supporting its international growth strategy and diversifying its revenue streams.

Pacira BioSciences partners with Molteni for European expansion

https://www.investing.com/news/company-news/pacira-biosciences-partners-with-molteni-for-european-expansion-93CH-4932025
Pacira BioSciences has announced a partnership with Molteni Farmaceutici for the distribution and commercialization of its postsurgical pain management drug, EXPAREL, in European markets. Molteni will receive exclusive rights, with initial launches planned for Italy, Germany, Austria, and Poland, and the first commercial sale expected in 2027. Additionally, Pacira granted inducement awards to new employees, including stock options and restricted stock units.

Pacira Announces Exclusive Agreement with Molteni

https://www.globenewswire.com/de/news-release/2026/10/05/3374473/0/en/pacira-announces-exclusive-agreement-with-molteni-farmaceutici-to-commercialize-exparel-in-the-european-union-and-united-kingdom.html
Pacira BioSciences has entered into an exclusive agreement with Molteni Farmaceutici to commercialize EXPAREL® (bupivacaine liposome injectable suspension) in the European Union and United Kingdom. This partnership aims to expand patient access to opioid-sparing postsurgical pain management across European markets, aligning with Pacira's 5x30 growth strategy. Molteni Farmaceutici will handle regulatory, market access, and commercialization activities, with the first commercial sale expected in 2027, while Pacira will receive an upfront payment, supply price, and royalties.

Pacira Biosciences, Inc. and Molteni Farmaceutici Announce Exclusive Agreement with Molteni Farmaceutici to Commercialize Exparel® in the European Union and United Kingdom

https://www.marketscreener.com/news/pacira-biosciences-inc-and-molteni-farmaceutici-announce-exclusive-agreement-with-molteni-farmaceu-ce785dd8da8bf024
Pacira BioSciences, Inc. has partnered with Molteni Farmaceutici to commercialize EXPAREL® (bupivacaine liposome injectable suspension) in the European Union and United Kingdom. Under the exclusive agreement, Molteni will handle regulatory, market access, and commercialization activities, starting with launches in Italy, Germany, Austria, and Poland in 2027, while Pacira will manufacture the drug. This collaboration aims to expand access to opioid-sparing postsurgical pain management across European markets.

Pacira Biosciences Grants Molteni Exclusive Rights to Commercialize EXPAREL in EU, UK

https://finance.yahoo.com/healthcare/articles/pacira-biosciences-grants-molteni-exclusive-124120164.html
Pacira Biosciences has granted Molteni Farmaceutici exclusive rights to commercialize EXPAREL in the European Union and the United Kingdom. This agreement will allow Molteni to distribute Pacira's product in key European markets. The full details of this premium article require a subscription to MT Newswires.
Advertisement

Pacira BioSciences partners with Molteni for European expansion By Investing.com

https://uk.investing.com/news/stock-market-news/pacira-biosciences-partners-with-molteni-for-european-expansion-93CH-4895347
Pacira BioSciences has partnered with Molteni Farmaceutici to distribute its postsurgical pain management drug, EXPAREL, across European markets. Molteni will receive exclusive distribution rights and plans to launch the product sequentially, starting with Italy, Germany, Austria, and Poland, with the first commercial sale expected in 2027. Pacira also reported granting inducement awards to two new employees, including stock options and restricted stock units.

Pacira BioSciences partners with Molteni for European expansion By Investing.com

https://ca.investing.com/news/stock-market-news/pacira-biosciences-partners-with-molteni-for-european-expansion-93CH-4865848
Pacira BioSciences has announced a partnership with Molteni Farmaceutici to expand the distribution of EXPAREL, its postsurgical pain management injectable, into European markets. Molteni will exclusively distribute and commercialize EXPAREL, with an initial launch planned for Italy, Germany, Austria, and Poland, and the first commercial sale expected in 2027. Additionally, Pacira granted inducement awards to two new employees, consisting of stock options and restricted stock units.

A postsurgery pain medicine is planned to launch in four countries; first sales are expected in 2027.

https://www.stocktitan.net/news/PCRX/pacira-announces-exclusive-agreement-with-molteni-farmaceutici-to-5dof6cngob01.html
Pacira BioSciences has signed an exclusive agreement with Molteni Farmaceutici to commercialize EXPAREL, a postsurgical pain treatment, in the European Union and United Kingdom. Pacira will receive an upfront payment, supply payments, and royalties, while Molteni will handle commercialization and plans sequential launches starting in 2027 in Italy, Germany, Austria, and Poland. Additionally, Pacira granted inducement awards to two new employees consisting of stock options and restricted stock units.

Pacira Announces Exclusive Agreement with Molteni

https://www.globenewswire.com/news-release/2026/10/05/3374473/0/en/pacira-announces-exclusive-agreement-with-molteni-farmaceutici-to-commercialize-exparel-in-the-european-union-and-united-kingdom.html
Pacira BioSciences has entered into an exclusive agreement with Molteni Farmaceutici to commercialize EXPAREL® (bupivacaine liposome injectable suspension) in the European Union and United Kingdom. This partnership aims to expand access to opioid-sparing postsurgical pain management and aligns with Pacira's 5x30 growth strategy. Molteni Farmaceutici will handle distribution, regulatory, and commercialization activities, with the first commercial sale expected in 2027.

Pacira BioSciences stock weighs Q2 growth and lower guidance

https://www.ad-hoc-news.de/boerse/news/corporate-news/pacira-biosciences-stock-weighs-q2-growth-and-lower-guidance/70224682
Pacira BioSciences (PCRX) reported Q2 2026 revenue of USD 192.4 million, exceeding expectations, but subsequently lowered its full-year revenue guidance due to the sale of iovera. Analysts maintain an "Outperform" consensus rating with price targets above the current stock price, suggesting potential upside despite the revised outlook. The stock closed 9.0 percent below its 52-week high, with a market capitalization of USD 991.6 million, presenting a valuation trade-off for investors.
Advertisement

Technical Reactions to PCRX Trends in Macro Strategies

https://news.stocktradersdaily.com/news_release/132/Technical_Reactions_to_PCRX_Trends_in_Macro_Strategies_100326081202_1791029522.html
Pacira Biosciences Inc. (NASDAQ: PCRX) is showing a neutral sentiment across all time horizons, suggesting sideways trading. The article outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles. Key support and resistance levels are identified, with an exceptional 34.1:1 risk-reward setup targeting a 9.5% gain versus 0.3% risk.

Pacira: More Sales, Less Adjusted EBITDA, Better Cash

https://orthotw.com/article/pacira-more-sales-less-adjusted-ebitda-better-cash
Pacira BioSciences reported a mixed second quarter with increased sales and substantially improved free cash flow, despite a decline in adjusted EBITDA. The company's recent divestiture of iovera complicates year-over-year comparisons, and future reports will need to demonstrate margin sustainability and cash conversion for the retained portfolio. Management's challenge is to prove that increased operating expenses will lead to durable returns and improved profitability.

Oppenheimer Initiates Pacira Biosciences at Outperform With $32 Price Target

https://www.marketscreener.com/news/oppenheimer-initiates-pacira-biosciences-at-outperform-with-32-price-target-ce785ad9df8bf724
Oppenheimer has initiated coverage on Pacira Biosciences (PCRX) with an Outperform rating and a $32 price target. This analyst action follows previous coverage initiations and price adjustments from other firms, highlighting ongoing analyst interest in the pharmaceutical company. Pacira BioSciences specializes in non-opioid pain management and is also developing a gene therapy for osteoarthritis.

Oppenheimer Initiates Pacira Biosciences at Outperform With $32 Price Target

https://finance.yahoo.com/markets/stocks/articles/oppenheimer-initiates-pacira-biosciences-outperform-104224208.html
Oppenheimer has initiated coverage of Pacira Biosciences (PCRX) with an "Outperform" rating and a $32 price target. This new rating is above the average analyst rating for PCRX, which is currently "overweight" with a mean price target of $29.67. The full MT Newswires article requires a premium subscription to read.

Pacira BioSciences stock falls 2.35 percent to USD 24.11

https://www.ad-hoc-news.de/boerse/news/nebenwerte/pacira-biosciences-stock-falls-2-35-percent-to-usd-24-11/70153353
Pacira BioSciences (PCRX) stock fell 2.35% to USD 24.11 on September 21, 2026, closing with a market capitalization of USD 961.07 million. This decline occurred despite the Nasdaq Composite gaining 2.26% on the same day, marking a 4.61 percentage point underperformance for Pacira. The company, a specialty and generic drug manufacturer, saw its equity value remain near the USD 1 billion threshold.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement